Rosetta and NYU form melanoma pact:
This article was originally published in Clinica
Executive Summary
Rosetta Genomics has joined up with the NYU Medical Center to develop a diagnostic test for melanoma, using Rosetta's microRNA technology. The partnership will involve the use of Rosetta's diagnostic engine to screen more than 700 microRNAs in order to identify a diagnostic signature for the disease. The collaborators hope to identify microRNAs that can be used as prognostic indicators for the overall survival of melanoma patients, and to predict the risk that the cancer will metastasise. Rehovot, Israel-based Rosetta already has a pact with US-based NYU to develop a line of early detection products for lung and mesothelioma cancers. The firm also hopes to launch three novel tests during 2008, one for cancer of unknown primary (CUP) and two for lung cancer.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.